List view / Grid view
6 September 2013 | By Takeda
FDA has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis...
6 September 2013 | By
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need...
5 September 2013 | By Capsugel
Capsugel and Bend Research have entered into a definitive agreement for Capsugel to acquire Bend Research as part of its DFS business unit...
5 September 2013 | By GlaxoSmithKline
In line with the Independent Data Monitoring Committee’s unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed...
4 September 2013 | By Merck
Merck has received approval from the U.S. FDA to manufacture bulk varicella at the company’s site in Durham...
4 September 2013 | By Novartis
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin...
4 September 2013 | By AstraZeneca
As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013...
4 September 2013 | By Abbott
Abbott announced promising preliminary results from a study presented at the ESC Congress 2013...
4 September 2013 | By Novartis
Robust efficacy of once-daily Ultibro® Breezhaler® (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro® LABA+LAMA combination for the treatment of COPD patients[1],[2],[3]...
3 September 2013 | By Sanofi
Prequalification makes the vaccine eligible for purchase by United Nations Agencies...
3 September 2013 | By Novartis
Ilaris® is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection[1]...
3 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...
3 September 2013 | By Amgen
First trial to evaluate cardiac myosin activator in patients with acute heart failure presented at ESC Congress 2013...
3 September 2013 | By O2PR LTD
Selcia Limited has entered into a drug discovery collaboration with Cantab Anti-Infectives...
3 September 2013 | By Johnson & Johnson
“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”
